Tiny drug particles aim to target tough breast, ovarian, and endometrial cancers
NCT ID NCT06738966
First seen Jan 17, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This early-stage trial is testing an experimental drug called BL0175, a nano-medicine designed to deliver treatment directly into tumors. It is for postmenopausal women with advanced or metastatic hormone-receptor-positive breast, ovarian, or endometrial cancer that has progressed after hormone therapy. The main goals are to check the drug's safety, find the highest safe dose, and see if it can slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL0175 (a nano-medicine that delivers an estrogen receptor down regulator directly into tumors)
What this could lead to
If it works, this could point toward a new treatment option for hormone-receptor-positive cancers that have stopped responding to standard hormone therapy.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.